
**Greater Manchester and Cheshire HPB Unit
Guidelines for the Assessment &
Management of Hepatobiliary and
Pancreatic Disease
Chapter 1**

Preface

Mission Statement of the Greater Manchester & Cheshire HPB Unit, CMFT

The HPB service in Manchester seeks to serve all equally, honestly and well and with skill and compassion.

Our service should be readily accessible, flexible and fair.

Our outcomes should be honestly, clearly and regularly reported.

We should contribute to the better understanding of HPB.

Ajith Siriwardena MD FRCS

Professor of Hepatobiliary Surgery, University of Manchester

Consultant and Lead Clinician HPB Unit, Manchester Royal Infirmary.

Cancer Lead Clinician, CMFT.

Contents

1.	Introduction	6
2.	The Greater Manchester & Cheshire HPB sMDT	10
2.1.	A description of the GM&C HPB sMDT service	11
2.2.	NHS England Strategic Clinical Network (SCN), Greater Manchester, Lancashire & South Cumbria	16
2.3.	Greater Manchester Clinical Commissioning Groups (CCG's)	17
2.4.	Greater Manchester & Cheshire Trusts and Acute Hospitals	18
3.	HPB cancer service in Greater Manchester and Cheshire - Model of Care	19
3.1.	Introduction	20
3.2.	Leadership	20
3.3.	Patient Pathway	21
3.4.	Joint Working	26
3.5.	Local Services	29
3.6.	Transport	30
3.7.	Audit of Outcomes	30
4.	Manchester Cancer Pathways	32
4.1.	Manchester Cancer	33
4.2.	Strategies for improving outcomes in HPB cancer	37
4.3.	Suspected Cancer Referral Pathway Liver, Pancreas & Bile Duct	38
4.4.	Manchester Cancer Investigations Pathway for Jaundice	39
4.5.	Guidelines for referral of patients with known or suspected colorectal liver metastases	40
4.6.	Criteria for referral of a patient with suspected HPB malignancy to the merged Greater Manchester specialist HPB MDT	41
5.	Assessment & Management of Liver Metastases	42
5.1.	Metachronous colorectal liver metastases (CRLM) staging algorithm	43
5.2.	Metachronous CRLM Treatment Algorithm	44
5.3.	Treatment order algorithm for synchronous CRLM	45
5.4.	Timing of treatment of synchronous CRLM	49
5.5.	Resection of patients with extrahepatic disease	49
5.6.	Consent	51
5.7.	Cardiopulmonary Exercise Testing Protocol	51
5.8.	Radiological Reporting Standards for CRLM	52
5.9.	Histopathology reporting proforma – Colorectal cancer metastasis	54
5.10.	Follow up after liver resection	55
5.11.	Treatment of Metastatic Neuroendocrine Tumours	56
5.12.	Management of GIST	57
5.13.	Treatment of liver metastases of unknown primary	59
5.14.	ECOG / WHO Performance Status	62
5.15.	Differentiation of human epithelial neoplasms based on Immunohistochemistry	63
6.	Hepatocellular carcinoma	64
6.1.	Introduction:	65
6.2.	HCC surveillance	65
6.3.	Screening for underlying liver disease:	66

6.4.	Diagnosis of HCC:	66
6.5.	Staging of HCC	67
6.6.	Surgical Resection	68
6.7.	Liver Transplantation	68
6.8.	Local Ablation:	69
6.9.	Chemoembolisation and other transcatheter therapies	70
6.10.	Systemic therapy	71
6.11.	Advanced disease:	72
6.12.	Long term follow-up:	72
6.13.	EASL-EORTC Surveillance recall policy and diagnostic algorithm	73
6.14.	Barcelona Clinic Liver Cancer strategy for diagnosis and staging of HCC	74
6.15.	TNM classification and histopathology reporting proforma – HCC	76
6.16.	Reporting proforma for liver resection: hepatocellular carcinoma	77
7.	Benign liver conditions	79
7.1.	Pyogenic liver abscess	80
7.2.	Management of hydatid cysts (cystic echinococcosis)	81
7.3.	Solitary & Polycystic liver disease	86
7.4.	Hepatocellular adenomas	88
7.5.	Acute Liver Failure	90
7.6.	Liver Transplantation: UK Selection Criteria	92
8.	Perihilar and intrahepatic cholangiocarcinoma	93
8.1.	BSG Guidelines for cholangiocarcinoma screening in primary sclerosing cholangitis	94
8.2.	Diagnosis and staging algorithm for cholangiocarcinoma	94
8.3.	The De Oliveira-Clavien (B,T,F,PV,HA,V,D,N,M) Classification System	95
8.4.	Criteria for unresectability	96
8.5.	Treatment algorithm for resectable disease	97
8.6.	Treatment algorithm for unresectable disease	98
8.7.	TNM classification and histopathology reporting proforma – Perihilar cholangiocarcinoma	99
8.8.	TNM Classification and histopathology reporting proforma – Intrahepatic cholangiocarcinoma	102
9.	Management of Gallbladder Disease	105
9.1.	Gallbladder polyps	106
9.2.	Laparoscopic Cholecystectomy	107
9.3.	Patient readmitted post-laparoscopic cholecystectomy	110
9.4.	Bile duct injury	111
9.5.	Diagnosis and staging of gallbladder cancer	119
9.6.	Treatment algorithm for Gallbladder Cancer	120
9.7.	Management of incidentally detected gallbladder cancer	121
9.8.	Extent of surgery for Gallbladder cancer	122
9.9.	TNM classification and histopathology reporting proforma – Gallbladder cancer	123
10.	Acute Pancreatitis	126
10.1.	Diagnosis	127
10.2.	Initial Management	127
10.3.	Definitions	127
10.4.	Severity Prediction	130
10.5.	Determine and treat the underlying aetiology	130
10.6.	Role of ERCP	130
10.7.	CT Scanning & Ultrasound	130

10.8.	Nutritional Support	131
10.9.	Antibiotics	131
10.10.	Management of gallstones	131
10.11.	Management of alcoholism	132
10.12.	Management of idiopathic acute pancreatitis	132
10.13.	Management of Abdominal Compartment Syndrome	133
10.14.	Management of Pancreatic Necrosis	135
10.15.	Indications for Referral to the specialist centre	136
10.16.	Radiology Guidelines in Acute Pancreatitis	137
11.	Chronic Pancreatitis	138
11.1.	Overview of management	139
11.2.	Diagnostic algorithm for chronic pancreatitis	140
11.3.	Aetiological Classification of Chronic Pancreatitis (TIGAR-O system)	141
11.4.	Treatment algorithm for chronic pancreatitis	142
11.5.	Nutritional Assessment, Treatment of PEI and Type 3c DM	143
11.6.	Autoimmune Pancreatitis – Principles of Diagnosis	144
11.7.	Autoimmune Pancreatitis – Treatment Algorithm	146
12.	Pancreatic cystic lesions	147
12.1.	Classification and salient features of the more common pancreatic cystic lesions	148
12.2.	Radiological reporting standards for pancreatic cystic lesions	148
12.3.	Algorithm for management of pancreatic cystic lesions	149
13.	Pancreatic cancer	150
13.1.	Algorithm for diagnosis and staging of pancreatic cancer	151
13.2.	Algorithm for treatment of pancreatic cancer	152
13.3.	Secondary screening for early pancreatic cancer	153
13.4.	Pancreatic cancer CT Staging	155
13.5.	TNM and JPS classification – pancreatic, ampullary and bile duct cancer	156
13.6.	Histopathology reporting proforma – Pancreatic carcinoma	158
13.7.	Histopathology reporting proforma –Ampulla of Vater Cancer	159
13.8.	Histopathology reporting proforma – Bile duct carcinoma	160
14.	Neuroendocrine Tumours	161
14.1.	Diagnostic algorithm for pancreatic neuroendocrine tumours (PNETs)	162
14.2.	Management of PNET	162
14.3.	Surgical management of resectable PNET	163
14.4.	Management of Residual/Progressive/Metastatic/Inoperable PNET	164
14.5.	ENETS TNM and WHO classification of PNET	165
14.6.	Histopathology reporting proforma for pancreatic neuroendocrine tumour resections	167
15.	General perioperative management	169
15.1.	HPB WHO Checklist	170
15.2.	ERAS Protocol for management of liver resection	174
15.3.	ERAS Protocol for perioperative management of Pancreatoduodenectomy	176
15.4.	Algorithm for reducing the risk of venous thromboembolism	178
15.5.	Algorithm for IV fluid therapy	180
15.6.	Acute Kidney Injury	181
15.7.	Composition of commonly used crystalloids	182
15.8.	Composition of common fluid losses	183

15.9.	Malnutrition Universal Screening Tool (MUST)	184
15.10.	Indications for nutrition support	185
15.11.	Nutritional Support and Refeeding syndrome	186
15.12.	Protocol for nutritional, anthropometric and clinical monitoring of nutrition support	188
15.13.	Protocol for laboratory monitoring of nutrition support	191
15.14.	HPB Quality Improvement Programme (QIP)	193
16.	HPB trauma	198
16.1.	Massive Haemorrhage Protocol	199
16.2.	Operative management of blunt hepatic trauma	201
16.3.	Non-operative management of adult blunt hepatic trauma	202
16.4.	Management of pancreatic injuries	203
16.5.	AAST Liver Injury Scale	204
16.6.	AAST Pancreas Organ Injury Scale	204
17.	Selected References	205

1. Introduction

The purpose of this guideline document is to aid better decision making. In medicine, we pride ourselves on our ability to produce quick and intuitive “end of the bed diagnoses” and answers to clinical questions. When tested against simple formulae, the response of experts is (almost always) inferior. Hence, these guidelines are a collection of formulae, algorithms and checklists that have been taken from the latest evidence based guidelines from the relevant specialist associations.

A second purpose is to fulfil our requirements to regulatory bodies. The Greater Manchester Cancer Summit 2012 determined that the Hepato-pancreato-biliary (HPB) surgical service for Greater Manchester and Cheshire patients should be established on a single acute hospital site and developed in a way that is fully compliant with national Improving Outcomes Guidance (IOG). In October 2014, the HPB services, provided by Pennine Acute Trust (PAT) at North Manchester General Hospital and by Central Manchester Foundation Trust, merged and moved to the Manchester Royal Infirmary (MRI) site at CMFT, creating a single specialist site for Greater Manchester and Cheshire patients. The rationale for this merger of services onto a single site is to create the best conditions for the development of the service as ‘world class’, improving both the quality of service provided and outcomes for patients through the centralisation and concentration of expertise and facilities on one hospital site. The Cancer Summit document, “The Delivery of World Class Specialist Cancer Surgery Services in the Greater Manchester and Cheshire Cancer System - A Framework Commissioning Specification, Jan 2013” states “each service must have a single set of governance arrangements, clinical guidelines, a single pathway and operational policy”. This guideline document fulfils that role, as well as meeting similar requirements from National Cancer Peer Review and NHS Commissioning Board Service Specifications.

The decision to produce this document was made by the Joint Implementation Group that oversaw the merger of the two Manchester HPB units. It was achieved by the following process: members of the North Manchester and MRI HPB MDTs and other interested parties met at a series of meetings over the course of 2013-14; the scope of the work was outlined; subgroups drafted their chapters, which were reviewed and amended by e-mail and at subsequent meetings; widespread consultations of all interested parties was achieved through the Manchester Cancer HPB Pathway Board; before final submission to the CMFT clinical governance committee.

Acknowledgements are due to all those who participated at these meetings and/or contributed to the production of these guidelines: *Prof. Ajith Siriwardena, Mr. Aali Sheen, Mr. Thomas Satyadas, Mr. Saurabh Jamdar, Mr. Derek O'Reilly, Mr. Rahul Deshpande, Mr. Nicola De'Liguori Carino, Dr. Steven Lee, Dr. Rishi Sethi, Dr. Rafik Filobos, Dr. Zahir Sherazi, Dr Eddie Tam, Dr Hans Ulrich Laasch, Sr. Debbie Clark, Dr. Alistair*

Makin, Dr. Jo Puleston, Dr. Luke Williams, Dr. Richard Hammonds, Dr. Martin Prince, Dr. Shaun Greer, Prof. Juan Valle, Dr. Richard Hubner, Dr. Saiffie Mullimitha, Dr. Michael Braun, Dr. Mark Saunders, Dr. Vivek Misra, Dr. Catherine McBain, Dr. Greg Wilson, Dr. Hassan Jurjees, Dr. Angela Lamarca, Dr. Mairead McNamara, Dr. Prakesh Manoharan, Dr. Mike Leahy, Dr. Claire Mitchell, Dr. Stephen McGrath and Dr. Emyr Benbow. Thanks are due to those junior medical staff whose greater computer literacy was availed of in the production of this guidance: *Mr. Munir Junejo, Ms. Jen Barrie, Dr. Tom Lee, Mr. Sot Tolofari, Miss Hema Sekhar, Mr. Mazier Khorshandi, Mr. Neil Harvey, Mr. Peter Coe,* and especially to *Mr. Vishnu V Chandrabalan* for his tireless contribution in maintaining and developing this document. Special thanks are also due to: *Mrs. Sarah Duff and Mr. Marc Besselink,* who both were guest speakers at our guidelines meetings and to: *Prof. Colin Johnson, Dr. Stephen Pereira and Mr. Marc Besselink* for sharing draft international guidelines in development. My sincere apologies to anyone that I have inadvertently forgotten to thank.

Derek O'Reilly,
Consultant HPB Surgeon,
Manchester,
September 2014.

Disclaimer

The information contained within, including but not limited to clinical practice guidelines and other guidance, is based on the best available evidence at the time of creation and is provided by CMFT/Manchester Cancer to assist providers in clinical decision making. The information should not be relied on as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new evidence may emerge between the time information is developed and when it is published or read. The information is not continually updated and may not reflect the most recent evidence. These guidelines are due for revision in January 2018. The information addresses only the topics specifically identified therein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular product or course of medical treatment. Further, the information is not intended to substitute for the independent professional judgment of the treating provider, as the information does not account for individual variation among patients. Recommendations reflect high, moderate or low confidence that the recommendation reflects the net effect of a given course of action. The use of words like “must,” “must not,” “should,” and “should not” indicate that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in certain cases. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. CMFT/Manchester Cancer provides this information on an “as is” basis, and makes no warranty, express or implied, regarding the information.

CMFT/Manchester Cancer specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. CMFT/Manchester Cancer assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.